SCHEMBL16872924

SCHEMBL16872924

CCOc1c(/C=C/c2ccc3cccc(OC)c3n2)cc(I)cc1OC(C)=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 18/20 0.66
▸ MEN1 O00255 16/20 0.66
▸ NPC1 O15118 13/20 0.66
▸ MAPT P10636 10/20 0.66
▸ SMN1; SMN2 Q16637 6/20 0.66
▸ LMNA P02545 4/20 0.66
▸ GAA P10253 1/20 0.66
▸ RAB9A P51151 11/20 0.59
▸ HTT P42858 3/20 0.59
▸ NPSR1 Q6W5P4 2/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2D6 P10635 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ AGTR1 P30556 3/20 0.56
▸ ALDH1A1 P00352 6/20 0.56
▸ HPGD P15428 4/20 0.56
▸ POLB P06746 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12282406 0.83 KMT2A (0.62) KMT2AMEN1NPC1MAPTSMN1; SMN2
SCHEMBL12280979 0.82 KMT2A (0.74) KMT2AMEN1NPC1MAPTSMN1; SMN2
SCHEMBL15613229 0.80 KMT2A (0.56) KMT2AMEN1NPC1MAPTSMN1; SMN2
SCHEMBL12281283 0.77 KMT2A (0.76) KMT2AMEN1NPC1MAPTSMN1; SMN2
SCHEMBL12281829 0.75 KMT2A (0.72) KMT2AMEN1NPC1MAPTSMN1; SMN2
SCHEMBL12280667 0.74 KMT2A (0.66) KMT2AMEN1NPC1MAPTSMN1; SMN2
SCHEMBL14681431 0.72 KMT2A (1.00) KMT2AMEN1NPC1MAPTSMN1; SMN2
SCHEMBL27952547 0.71 KMT2A (0.58) KMT2AMEN1NPC1MAPTSMN1; SMN2
SCHEMBL12281794 0.70 KMT2A (0.73) KMT2AMEN1NPC1MAPTSMN1; SMN2
SCHEMBL12281111 0.69 KMT2A (0.60) KMT2AMEN1NPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348295-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA SIRGA ADVANCED BIOPHARMA INC (US) 2017-12-07 — — US disclosed
US-9775835-B2 Small molecule inhibitors of viral protein interactions with human t-RNA SIRGA ADVANCED BIOPHARMA, INC. (US) 2017-10-03 — — US disclosed
US-20150190384-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA SIRGA ADVANCED BIOPHARMA, INC. (US) 2015-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348295-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA NSUN3, TARBP1, TRDMT1 KMT2A 2508/4885MEN1 3917/4885NPC1 2010/4885
US-20150190384-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA NSUN3, TARBP1, TRDMT1 KMT2A 2752/4885MEN1 3866/4885NPC1 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback